CN100372539C - 用于治疗恶性疾病、包含双膦酸类化合物、cox-2抑制剂和紫杉醇的组合的药物组合物 - Google Patents

用于治疗恶性疾病、包含双膦酸类化合物、cox-2抑制剂和紫杉醇的组合的药物组合物 Download PDF

Info

Publication number
CN100372539C
CN100372539C CNB028207823A CN02820782A CN100372539C CN 100372539 C CN100372539 C CN 100372539C CN B028207823 A CNB028207823 A CN B028207823A CN 02820782 A CN02820782 A CN 02820782A CN 100372539 C CN100372539 C CN 100372539C
Authority
CN
China
Prior art keywords
cox
inhibitor
phenyl
phosphonic acids
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028207823A
Other languages
English (en)
Chinese (zh)
Other versions
CN1703226A (zh
Inventor
艾伦·利普顿
洛伊斯·马里·威特斯
J·格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Novartis Pharmaceuticals Corp
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1703226A publication Critical patent/CN1703226A/zh
Application granted granted Critical
Publication of CN100372539C publication Critical patent/CN100372539C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028207823A 2001-10-19 2002-10-18 用于治疗恶性疾病、包含双膦酸类化合物、cox-2抑制剂和紫杉醇的组合的药物组合物 Expired - Fee Related CN100372539C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592101P 2001-10-19 2001-10-19
US60/345,921 2001-10-19

Publications (2)

Publication Number Publication Date
CN1703226A CN1703226A (zh) 2005-11-30
CN100372539C true CN100372539C (zh) 2008-03-05

Family

ID=23357099

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028207823A Expired - Fee Related CN100372539C (zh) 2001-10-19 2002-10-18 用于治疗恶性疾病、包含双膦酸类化合物、cox-2抑制剂和紫杉醇的组合的药物组合物

Country Status (25)

Country Link
US (1) US7345088B2 (enExample)
EP (1) EP1443942B1 (enExample)
JP (1) JP2005506371A (enExample)
KR (1) KR20040066103A (enExample)
CN (1) CN100372539C (enExample)
AT (1) ATE382347T1 (enExample)
AU (1) AU2002363089B2 (enExample)
BR (1) BR0213410A (enExample)
CA (1) CA2461085A1 (enExample)
CO (1) CO5570672A2 (enExample)
DE (1) DE60224429T2 (enExample)
DK (1) DK1443942T3 (enExample)
EC (1) ECSP045054A (enExample)
ES (1) ES2301710T3 (enExample)
HU (1) HUP0402061A3 (enExample)
IL (2) IL161090A0 (enExample)
MX (1) MXPA04003671A (enExample)
NO (1) NO20042056L (enExample)
NZ (1) NZ532282A (enExample)
PL (1) PL367707A1 (enExample)
PT (1) PT1443942E (enExample)
RU (1) RU2317819C2 (enExample)
SI (1) SI1443942T1 (enExample)
WO (1) WO2003035081A1 (enExample)
ZA (1) ZA200402089B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (pt) 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2001054688A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2001054688A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
RU2317819C2 (ru) 2008-02-27
EP1443942B1 (en) 2008-01-02
ZA200402089B (en) 2005-06-22
DE60224429D1 (de) 2008-02-14
CA2461085A1 (en) 2003-05-01
BR0213410A (pt) 2004-11-03
ECSP045054A (es) 2004-05-28
IL161090A (en) 2010-04-15
AU2002363089B2 (en) 2006-02-16
HK1080733A1 (en) 2006-05-04
HUP0402061A2 (hu) 2005-02-28
RU2004115337A (ru) 2005-04-20
MXPA04003671A (es) 2005-06-20
CO5570672A2 (es) 2005-10-31
PL367707A1 (en) 2005-03-07
NO20042056L (no) 2004-05-18
DK1443942T3 (da) 2008-05-19
EP1443942A1 (en) 2004-08-11
DE60224429T2 (de) 2008-12-18
SI1443942T1 (sl) 2008-08-31
CN1703226A (zh) 2005-11-30
US20050014726A1 (en) 2005-01-20
WO2003035081A1 (en) 2003-05-01
KR20040066103A (ko) 2004-07-23
PT1443942E (pt) 2008-04-07
ATE382347T1 (de) 2008-01-15
US7345088B2 (en) 2008-03-18
IL161090A0 (en) 2004-08-31
NZ532282A (en) 2006-02-24
JP2005506371A (ja) 2005-03-03
HUP0402061A3 (en) 2007-05-29
ES2301710T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
CN1277545C (zh) 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途
TWI275393B (en) Use of bisphosphonates for pain treatment
US20090209493A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
JP2010159271A (ja) エポシロンを含有する組合せ剤およびその医薬上の使用
CN100372539C (zh) 用于治疗恶性疾病、包含双膦酸类化合物、cox-2抑制剂和紫杉醇的组合的药物组合物
CN100593401C (zh) 芳香酶抑制剂和双膦酸酯的组合
AU2002363089A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol
HK1080733B (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates,a cox-2 inhibitor and a taxol
US20050209198A1 (en) Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
CN101669958A (zh) 二膦酸类化合物的药物应用
HK1080734B (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080733

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NOVANNIS COMPANY; PENNSYLVANIA RESEARCH FOUNDATIO

Free format text: FORMER OWNER: NOVANNIS COMPANY; GREEN JONATHAN; LIPTON ALLAN

Effective date: 20080711

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080711

Address after: Basel, SUI

Co-patentee after: The Penn State Research Foundation

Patentee after: Novartis

Address before: Basel, SUI

Co-patentee before: Green Jonathan

Patentee before: Novartis

Co-patentee before: Lipton Allan

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1080733

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080305

Termination date: 20091118